Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
The bactericidal activities against Mycobacterium leprae of single or multiple doses of various combinations of new antileprosy drugs [minocycline (MINO), clarithromycin (CLARI), ofloxacin (OFLO), and sparfloxacin (SPFX)] and/or rifampin (RMP) were titrated in immunocompetent mice by the proportional bactericidal method. Drugs were administered by gavage at the following dosages (mg/kg) per dose: RMP 10, MINO 25, CLARI 100, OFLO 150, and SPFX 50. All 15 regimens exerted significant bactericidal activities, at least 96% of viables were killed. The activity of a single dose MINO + CLARI was only slightly inferior to that of RMP, and the activities of a single dose OFLO/SPFX + MINO + CLARI were similar to that of RMP. This suggests that either MINO + CLARI or OFLO/SPFX + MINO + CLARI may be administered once monthly together with RMP 600 mg for the treatment of multibacillary (MB) leprosy, and monthly administration of MINO + CLARI or OFLO/SPFX + MINO + CLARI may also be employed for the treatment of RMP-resistant MB leprosy. Because the killing effects of multiple doses of the combinations were so powerful, comparison of the bactericidal activities of these regimens was beyond the sensitivity of the immunocompetent mouse model, and are being tested in the nude mouse model. Although SPFX is more active against M. leprae than OFLO on a weight-to-weight basis, when both drugs were administered in mice at dosages equivalent to clinically tolerated dosages in humans, SPFX did not show more superiority than OFLO, and its real advantage over OFLO in the treatment of leprosy remains unclear.
Ji
B
B
Faculté de Médecine Pitié-Salpêtrière, Paris, France.
Perani
E G
EG
Petinon
C
C
Grosset
J H
JH
D000818:Animals; D017291:Clarithromycin / Q000008:administration & dosage; D004195:Disease Models, Animal; D005260:Female; D024841:Fluoroquinolones; D005528:Foot / Q000382:microbiology; D006614:Hindlimb / Q000382:microbiology; D007121:Immunocompetence; D007917:Leprostatic Agents / Q000494:pharmacology*; D007918:Leprosy / Q000188:drug therapy*; D051379:Mice; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000008:administration & dosage; D009166:Mycobacterium leprae / Q000187:drug effects*; D015242:Ofloxacin / Q000008:administration & dosage; D015363:Quinolones / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage*
D024841:Fluoroquinolones; D007917:Leprostatic Agents; D015363:Quinolones; D015242:Ofloxacin; D008911:Minocycline; D017291:Clarithromycin; C061363:sparfloxacin; D012293:Rifampin